Immediate post-exposure prophylaxis after tetanus prone injuries in patients who are not adequately vaccinated, whose immunization status is not known w/ certainty or w/ severe deficiency in antibody production. Therapy of clinically manifested tetanus.
IMAdult & childnProphylaxis of tetanus prone wounds 250 IU, may be increased to 500 IU. Extensive burns Administer 2nd inj of 250 IU after exudative phase of the burn has subsided (about 36 hr after onset of the burn). Therapy of clinically manifested tetanus 3,000-6,000 IU as single dose.
Allergic reactions including fall in BP, dyspnoea, cutaneous reactions; chills, fever, headache, malaise, nausea, vomiting, arthralgia & moderate back pain; CV reactions if inadvertently injected IV; local reactions at the inj site (local pain, tenderness or swelling).
May impair the efficacy of live attenuated virus vaccines eg, measles, rubella, mumps & varicella vaccines for a period of up to 3 mth. May result in misleading +ve test results in serological testing due to transitory rise of passively transferred Abs after inj. May interfere w/ some serological tests for red cell allo-Abs (eg, Coombs' test).
Sign Out
 250 IU_mLc83b3402-7e78-4524-9c04-a5ee00fa6fc9.GIF)
